Overview
Pediatric orthopedics firm's preliminary Q4 revenue beat analyst expectations
Company reported record preliminary full year 2025 revenue growth of 15% yr/yr
Company projects 2026 revenue growth of 11% to 13% and $25 mln adjusted EBITDA
Outlook
OrthoPediatrics projects 2026 revenue between $262 mln and $266 mln
Company expects 2026 adjusted EBITDA of approximately $25 mln
OrthoPediatrics sees specialty bracing as a strategic growth driver
Result Drivers
TRAUMA AND DEFORMITY - Trauma and Deformity and Scoliosis implant businesses drove revenue growth and profitability, per CEO David Bailey
SPECIALTY BRACING - OPSB business seen as a strategic catalyst and capital-efficient driver of revenue and earnings
EUMDR CERTIFICATION - Achieved EUMDR certification for various products, potentially supporting future growth
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $61.30 mln | $59.28 mln (8 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for OrthoPediatrics Corp is $23.50, about 28.3% above its January 9 closing price of $18.31
Press Release: ID:nGNX1BkhK5
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)